190 related articles for article (PubMed ID: 38467982)
21. Neoantigen Specific T Cells Derived From T Cell-Derived Induced Pluripotent Stem Cells for the Treatment of Hepatocellular Carcinoma: Potential and Challenges.
Lu F; Ma XJ; Jin WL; Luo Y; Li X
Front Immunol; 2021; 12():690565. PubMed ID: 34054880
[TBL] [Abstract][Full Text] [Related]
22. [Development of "Off the Shelf" T Cells for Cancer Immunotherapy].
Nagano S; Kawamoto H
Gan To Kagaku Ryoho; 2023 May; 50(5):561-566. PubMed ID: 37218312
[TBL] [Abstract][Full Text] [Related]
23. Engineered and banked iPSCs for advanced NK- and T-cell immunotherapies.
Cichocki F; van der Stegen SJC; Miller JS
Blood; 2023 Feb; 141(8):846-855. PubMed ID: 36327161
[TBL] [Abstract][Full Text] [Related]
24. Generation of Antigen-Specific T Cells from Human Induced Pluripotent Stem Cells.
Nishimura T; Nakauchi H
Methods Mol Biol; 2019; 1899():25-40. PubMed ID: 30649763
[TBL] [Abstract][Full Text] [Related]
25. Adoptive Transfer of CD8+ T Cells Generated from Induced Pluripotent Stem Cells Triggers Regressions of Large Tumors Along with Immunological Memory.
Saito H; Okita K; Chang AE; Ito F
Cancer Res; 2016 Jun; 76(12):3473-83. PubMed ID: 27197199
[TBL] [Abstract][Full Text] [Related]
26. Reprogramming of Tumor-reactive Tumor-infiltrating Lymphocytes to Human-induced Pluripotent Stem Cells.
Islam SMR; Maeda T; Tamaoki N; Good ML; Kishton RJ; Paria BC; Yu Z; Bosch-Marce M; Bedanova NM; Liu C; Kruhlak MJ; Restifo NP; Vizcardo R
Cancer Res Commun; 2023 May; 3(5):917-932. PubMed ID: 37377887
[TBL] [Abstract][Full Text] [Related]
27. Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells.
Saetersmoen ML; Hammer Q; Valamehr B; Kaufman DS; Malmberg KJ
Semin Immunopathol; 2019 Jan; 41(1):59-68. PubMed ID: 30361801
[TBL] [Abstract][Full Text] [Related]
28. EZH1 repression generates mature iPSC-derived CAR T cells with enhanced antitumor activity.
Jing R; Scarfo I; Najia MA; Lummertz da Rocha E; Han A; Sanborn M; Bingham T; Kubaczka C; Jha DK; Falchetti M; Schlaeger TM; North TE; Maus MV; Daley GQ
Cell Stem Cell; 2022 Aug; 29(8):1181-1196.e6. PubMed ID: 35931029
[TBL] [Abstract][Full Text] [Related]
29. Trends in cell medicine: from autologous cells to allogeneic universal-use cells for adoptive T-cell therapies.
Kawamoto H; Masuda K
Int Immunol; 2024 Feb; 36(2):65-73. PubMed ID: 38189591
[TBL] [Abstract][Full Text] [Related]
30. Generation of TCR-Expressing Innate Lymphoid-like Helper Cells that Induce Cytotoxic T Cell-Mediated Anti-leukemic Cell Response.
Ueda N; Uemura Y; Zhang R; Kitayama S; Iriguchi S; Kawai Y; Yasui Y; Tatsumi M; Ueda T; Liu TY; Mizoro Y; Okada C; Watanabe A; Nakanishi M; Senju S; Nishimura Y; Kuzushima K; Kiyoi H; Naoe T; Kaneko S
Stem Cell Reports; 2018 Jun; 10(6):1935-1946. PubMed ID: 29805109
[TBL] [Abstract][Full Text] [Related]
31. [Development of antigen-receptor modified allogeneic T cell from iPS cells for cancer immunotherapy].
Kaneko S
Rinsho Ketsueki; 2022; 63(9):1279-1289. PubMed ID: 36198554
[TBL] [Abstract][Full Text] [Related]
32. Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells.
Ueda T; Kumagai A; Iriguchi S; Yasui Y; Miyasaka T; Nakagoshi K; Nakane K; Saito K; Takahashi M; Sasaki A; Yoshida S; Takasu N; Seno H; Uemura Y; Tamada K; Nakatsura T; Kaneko S
Cancer Sci; 2020 May; 111(5):1478-1490. PubMed ID: 32133731
[TBL] [Abstract][Full Text] [Related]
33. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
[TBL] [Abstract][Full Text] [Related]
34. Emerging NK cell therapies for cancer and the promise of next generation engineering of iPSC-derived NK cells.
Maddineni S; Silberstein JL; Sunwoo JB
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580928
[TBL] [Abstract][Full Text] [Related]
35. Induced pluripotent stem cell-derived engineered T cells, natural killer cells, macrophages, and dendritic cells in immunotherapy.
Xue D; Lu S; Zhang H; Zhang L; Dai Z; Kaufman DS; Zhang J
Trends Biotechnol; 2023 Jul; 41(7):907-922. PubMed ID: 36858941
[TBL] [Abstract][Full Text] [Related]
36. [Immune cell therapy using iPS cells].
Yano H; Kaneko S
Rinsho Ketsueki; 2018; 59(2):225-231. PubMed ID: 29515078
[TBL] [Abstract][Full Text] [Related]
37. Prospects for Development of Induced Pluripotent Stem Cell-Derived CAR-Targeted Immunotherapies.
Mazza R; Maher J
Arch Immunol Ther Exp (Warsz); 2021 Dec; 70(1):2. PubMed ID: 34897554
[TBL] [Abstract][Full Text] [Related]
38. Selection of Tumor-Specific Cytotoxic T Lymphocytes in Acute Myeloid Leukemia Patients Through the Identification of T-Cells Capable to Establish Stable Interactions With the Leukemic Cells: "Doublet Technology".
García-Guerrero E; Sánchez-Abarca LI; Domingo E; Ramos TL; Bejarano-García JA; Gonzalez-Campos JA; Caballero-Velázquez T; Pérez-Simón JA
Front Immunol; 2018; 9():1971. PubMed ID: 30233577
[TBL] [Abstract][Full Text] [Related]
39. Successful organoid-mediated generation of iPSC-derived CAR-T cells.
Kaneko S
Cell Stem Cell; 2022 Apr; 29(4):493-495. PubMed ID: 35395182
[TBL] [Abstract][Full Text] [Related]
40. Sustainable Antiviral Efficacy of Rejuvenated HIV-Specific Cytotoxic T Lymphocytes Generated from Induced Pluripotent Stem Cells.
Miki S; Kawai Y; Nakayama-Hosoya K; Iwabuchi R; Terahara K; Tsunetsugu-Yokota Y; Koga M; Matano T; Kaneko S; Kawana-Tachikawa A
J Virol; 2022 Mar; 96(6):e0221721. PubMed ID: 35107374
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
